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Cardiovascular diseases are the leading cause of death in schizophrenia. Patients with schizophrenia show evidence of concentric
cardiac remodelling (CCR), defined as an increase in left-ventricular mass over end-diastolic volumes. CCR is a predictor of cardiac
disease, but the molecular pathways leading to this in schizophrenia are unknown. We aimed to explore the relevance of
hypertensive and non-hypertensive pathways to CCR and their potential molecular underpinnings in schizophrenia. In this
multimodal case–control study, we collected cardiac and whole-body fat magnetic resonance imaging (MRI), clinical measures, and
blood levels of several cardiometabolic biomarkers known to potentially cause CCR from individuals with schizophrenia, alongside
healthy controls (HCs) matched for age, sex, ethnicity, and body surface area. Of the 50 participants, 34 (68%) were male.
Participants with schizophrenia showed increases in cardiac concentricity (d= 0.71, 95% CI: 0.12, 1.30; p= 0.01), indicative of CCR,
but showed no differences in overall content or regional distribution of adipose tissue compared to HCs. Despite the cardiac
changes, participants with schizophrenia did not demonstrate activation of the hypertensive CCR pathway; however, they showed
evidence of adipose dysfunction: adiponectin was reduced (d=−0.69, 95% CI: −1.28, −0.10; p= 0.02), with evidence of activation
of downstream pathways, including hypertriglyceridemia, elevated C-reactive protein, fasting glucose, and alkaline phosphatase. In
conclusion, people with schizophrenia showed adipose tissue dysfunction compared to body mass-matched HCs. The presence of
non-hypertensive CCR and a dysmetabolic phenotype may contribute to excess cardiovascular risk in schizophrenia. If our results
are confirmed, acting on this pathway could reduce cardiovascular risk and resultant life-years lost in people with schizophrenia.
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INTRODUCTION
Schizophrenia is a major mental illness with a lifetime prevalence
of 1% of the world population, and is amongst the top causes of
global disease burden in young adults [1]. Patients with
schizophrenia have 2–3 times higher mortality than the general
population [2] and up to 15 years shorter life expectancy [3, 4].
Mortality due to natural causes is eight times higher than
expected [2], predominantly due to higher prevalence of
comorbidities including type 2 diabetes, obesity, and cardiovas-
cular disease (CVD) [5]. CVD is the leading medical cause of death
in schizophrenia [6], averaging ~14 life-years lost [7], or 60% of
deaths [8].
Previous research has shown evidence for cardiac alterations in
people with schizophrenia indicative of concentric cardiac
remodelling (CCR) [9], myocardial tissue fibrosis, and/or inflamma-
tion [10]. CCR — the increase in the ratio of left ventricular (LV)
mass over end-diastolic volume — is one of the strongest
predictors of future CVD endpoints such as myocardial infarction,
coronary insufficiency, heart failure, and stroke [11], while
myocardial fibrosis independently predicts both cardiovascular
and all-cause mortality [12]. Therefore, the changes found in
chronic schizophrenia might account for part of the additional
cardiovascular mortality in schizophrenia.
Two main pathological pathways lead to CCR; the most
common, the hypertensive pathway, is a response to chronic
hypertension, both locally on the myocardium causing cardio-
myocyte stress, and systemically, as mediated by activation of the
renin–angiotensin–aldosterone system, which has potent pro-
fibrotic and pro-hypertrophic effects on the myocardium [13] (Fig.
1).
The non-hypertensive pathway involves a combination of
inflammatory and dysmetabolic changes leading to cardiomyo-
cyte hypertrophy and myo-fibroblast activation [13].
People with chronic schizophrenia have adipose tissue dysfunc-
tion, compared to body mass- and fat volume-matched healthy
controls (HCs) [14]. Adipose tissue dysfunction is a pro-
inflammatory state associated with increased C-reactive protein
(CRP) levels [15], insulin resistance [16], and decreased production
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of adiponectin [16]. Both insulin resistance [14] and low
adiponectin [17] have been reported in treated schizophrenia.
Reduced adiponectin is associated with a pro-inflammatory state
[18, 19] and insulin resistance [19] in the general population.
Reduced adiponectin levels are also associated with elevated
triglycerides and low-density lipoproteins (LDLs), [20] and with
endothelial dysfunction [21].
Figure 1 shows other potential downstream effects of adipose
tissue dysfunction, including non-alcoholic fatty liver disease (NAFLD)
[22, 23], found to have a higher prevalence in schizophrenia [24].
As inflammation [25], insulin resistance [26], NAFLD [27],
hyperlipidaemias [13], and endothelial dysfunction [28] are all
independently associated with CCR, adipose tissue dysfunction,
with its associated downstream effects, might represent a
plausible non-hypertensive pathway to CCR in schizophrenia.
The aim of this study was therefore to determine whether there
is evidence for the activation of the hypertensive or non-
hypertensive molecular pathways to CCR in schizophrenia.
Given the prior evidence consistent with cardiac inflammation
in schizophrenia [10], we hypothesised that there would be lower
levels of adiponectin and elevated glucoregulatory and inflam-
matory markers consistent with activation of the non-hypertensive
pathway in patients with schizophrenia.
METHODS
Participants
Patients with schizophrenia were recruited from South London and the
Maudsley NHS Foundation Trust and from Central and North West London
NHS Foundation Trust, in the UK. Matched HCs were recruited after
matching for age (+/−3 years), ethnicity, sex, and body surface area (BSA
+/−0.2, a parameter similar to body mass index (BMI), which is the
consensus method do index cardiac parameters [29]; calculated using the
Mosteller formula (Height [cm] ×Weight [kg]/3600)½) through the Ham-
mersmith Hospital Healthy Volunteer Panel, London, UK.
The inclusion criterion for patients was an International Classification of
Diseases, Tenth Revision diagnosis of schizophrenia. Exclusion criteria for all
participants were: age <18 or >65 years; pregnancy or breastfeeding; a
history of cardiometabolic disease, including diabetes, diagnosis of
hypertension, dyslipidaemia, ischaemic heart disease, any vascular disorder,
other history of congenital/structural cardiac disease; or history of significant
or continuing substance abuse and contra-indications to magnetic resonance
imaging (MRI). An additional exclusion criterion for HCs was a personal or
first-degree family history of schizophrenia or other psychotic disorder.
The patient sample in this study overlaps with our previously published
MRI studies, including cardiac [9, 10] and body fat [30] measures by MRI,
while HCs show only partial overlap. Further details are in Supplementary
Methods.
Assessment of participants
Physical assessment, study questionnaires, phlebotomy, and MRI were all
performed during the same study visit. All patients were assessed at the time
of imaging using the Positive and Negative Syndrome Scale for Schizophrenia
[31] by a study psychiatrist. Further details are in Supplementary Methods.
Blood collection and analysis protocol
Blood samples were collected from all participants after at least 6 h of fasting.
These were immediately refrigerated, and serum/plasma separation was
performed within 30min. Samples were then frozen at −80 °C for later batch
processing. Adipokines (leptin and adiponectin), liver function (alkaline
phosphatase (ALP), gamma-glutamyltransferase (GGT), alanine aminotransferase
(ALT)), fat metabolism (triglycerides, high-density lipoprotein (HDL) and LDL),
inflammation (high-sensitivity CRP (hsCRP)), glucose sensitivity (fasting glucose
and insulin), endothelin-1, renin, brain natriuretic peptide, and troponin-I were
measured. Processing was performed after maximum 4 years with no
intercurrent freeze–thaw cycles. The Homeostatic Model Assessment for Insulin
Resistance (HOMA-IR) was calculated as fasting insulin (mIU/l) × fasting glucose
(nmol/l)/22.5 [32]. Further details are in Supplementary Methods.
MRI protocol
MRI was performed at a single site for all subjects, who were recruited
between September 2016 and May 2019. Scanning was undertaken on a
3T Siemens Magnetom Prisma (Erlangen, Germany) using a combination of
the 18-channel body coil and 12 elements of the 32-channel spine coil. All
imaging was acquired with breathing suspended at expiration.
Figure 2 demonstrates the assessment of cardiac function and mass,
native T1, pulse-wave velocity (PWV), and whole-body fat through MRI.
Further details are in Supplementary Methods, alongside a description of
MRI analysis methods.
Statistical analysis
Data normality was assessed by inspecting distribution plots and tested
using Shapiro–Wilk tests. Blood metabolite distributions were skewed to
Fig. 1 Hypertensive and non-hypertensive molecular pathways to concentric cardiac remodelling. NAFLD non-alcoholic fatty liver disease,
ALP alkaline phosphatase, GGT gamma-glutamyltransferase, hsCRP high-sensitivity C-reactive protein, LDL and HDL low- and high-density
lipoprotein, HOMA-IR Homeostatic Model Assessment for Insulin Resistance, PWV pulse-wave velocity, BNP brain natriuretic peptide, ET-1
endothelin-1, SBP and DBP systolic and diastolic blood pressure. Graphic element credit: GraphicsRF/Shutterstock.com.
E.F. Osimo et al.
2
Translational Psychiatry          (2021) 11:614 
the right and showed a normal distribution after log transformation.
Differences among patients and controls were tested using χ2 tests for
categorical variables, Kruskal–Wallis (KW) tests by ranks for non-normally
distributed values, and analysis of variance for normally distributed
measures. Effect sizes were calculated on normally distributed or
transformed data using Cohen’s d measure, as implemented in [33].
Logistic regression was used to test for differences in metabolite
concentrations after adjusting for smoking, with diagnosis as the outcome
and log(metabolite)+ smoking status as predictors. To explore any
relationship between CCR pathway metabolites and concentricity, linear
regression was used to correlate concentricity to the natural logarithm of
the metabolite. The overall proportion of variance explained by linear
models was calculated using R2 measures. Further details are in
Supplementary Methods.
RESULTS
The study comprised a total of 50 subjects — 26 patients with
treated, chronic schizophrenia and 24 HCs. Two matched HCs
were excluded due to poor image quality. Subject characteristics
are described in Table 1. At the time of assessment, all patients
were treated with antipsychotics (N= 23 on clozapine, and N= 3
on olanzapine). There were no group differences in age, sex,
ethnicity, BSA, physical activity levels, and systolic or diastolic
blood pressure (BP). However, patients smoked significantly more
than the group controls (Table 1).
Cardiac and body fat measurements in patients with
schizophrenia and matched HCs
Table 2 describes MRI-derived cardiac and fat measures by
diagnostic status. Wilk’s test for case–control differences in
continuous cardiac measures was significant (Lambda= 0.74, df
= 3, p= 0.04). The post hoc tests showed that LV concentricity (d
= 0.71, p= 0.01) and native septal T1 (d= 0.77, p= 0.049) were
higher in people with a diagnosis of schizophrenia compared to
matched HCs with medium-to-large effect sizes. Mean concen-
tricity in patients was above reference ranges for male adult
populations, with 19/26 (73%) of patients and 12/24 (50%) of HCs
over the reference range.
There were no significant differences between groups in PWV
(d= 0.54, p= 0.08), and mean values were within reference ranges
for both cases and controls.
Wilk’s test for case–control differences in continuous fat
measures was not significant (Lambda= 0.98, df= 3, p= 0.92).
There was no significant difference in fat volumes (total, visceral
and visceral to total ratio) between patients and HCs (Table 2).
CCR hypertensive pathway in schizophrenia and matched HCs
Wilk’s test for case–control differences in continuous non-hypertensive
pathway measures was not significant (Lambda= 0.85, df= 6, p=
0.42). There were no differences in either systolic or diastolic BP, PWV











Fig. 2 Magnetic resonance images demonstrating the assessment of cardiac function and mass, native T1, pulse-wave velocity, and
whole-body fat. A Whole body fat. Visceral (green) and subcutaneous (purple) adipose tissue segmentations shown on coronal reformat of
whole-body fat image. B–D Native T1. Representative native T1 map for healthy control (B) and a patient with chronic schizophrenia (C). Each
slice was semi-automatically segmented with endocardial (red) and epicardial (green) borders and divided into six segments (D). Native
myocardial T1 time was calculated as the mean T1 time the two septal segments (black arrows). E, F Ventricular function and mass.
Endocardial and epicardial contours of the left and right ventricle in diastole (E) and systole (F). Segmentation shows myocardium (orange),
left ventricular (LV) cavity (dark orange), and right ventricular (RV) cavity (purple). G Pulse-wave velocity. Transverse cardiac magnetic
resonance imaging slice through the aortic arch displaying the magnitude (dotted white slice) with velocity encoded flow through the
ascending aorta (AA) and descending aorta (DA). Path length was determined by markers (X) creating a three-dimensional Bezier curve (white
line) through the centre of the aorta that intersected the plane at which flow measurements were acquired.
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renin levels, N-terminal-prohormone brain natriuretic peptide levels, or
troponin I levels (measured to rule out concurrent myocardial damage,
e.g. myocarditis) (Supplementary Fig. 1).
CCR non-hypertensive pathway in schizophrenia and matched
HCs
We obtained at least one measure for each step of the non-
hypertensive pathway represented in Fig. 1 from our participants.
Wilk’s test for case–control differences in continuous non-hypertensive
pathway measures was significant (Lambda= 0.35, df= 13, p< 0.001).
Figure 3A shows that, among the measures of adipose tissue
function, patients had reduced levels of adiponectin (d=−0.69,
95% confidence interval (CI): −1.28, −0.10; KW p= 0.02) compared
to controls; there was no difference in levels of leptin between
patients and controls (d= 0.25, 95% CI: −0.32, 0.82; KW p= 0.10).
Patients showed elevated levels of hsCRP (d= 0.02, 95% CI: −0.54,
0.59; KW p= 0.002; odds ratio for CRP >3mg/l in patients vs HCs:
5.83, 95% CI: 1.56, 21.87; Fig. 3C) compared to controls. Fasting
glucose levels (d= 0.96, 95% CI: 0.35, 1.57; KW p= 0.003) and the
HOMA insulin resistance index (d= 0.76, 95% CI: 0.16, 1.36; KW p=
0.049) were increased in patients compared to controls (Fig. 3C);
however, the difference in fasting insulin levels between the two
groups was not statistically significant despite a medium/large
effect size (d= 0.77, 95% CI: 0.18, 1.36; KW p= 0.12). Triglyceride
levels were increased in patients compared to controls (d= 0.82,
95% CI: 0.23, 1.41; KW p < 0.001); HDL-cholesterol levels were
reduced in patients (d=−0.78, 95% CI: −1.37, −0.19; KW p= 0.01).
There was no difference in LDL-cholesterol levels between the two
groups (d= 0.60, 95% CI: 0.02, 1.18; KW p= 0.06) (Fig. 3B).
Furthermore, patients showed significant elevations of circulat-
ing endothelin-1 levels, a pro-fibrotic, pro-hypertrophic, vasoactive
factor released by endothelial cells in response to endothelial
stress (d= 0.70, 95% CI: 0.11, 1.28; KW p= 0.02; Fig. 3C).
Patients showed evidence of elevated ALP (d= 1.18, 95% CI:
0.57, 1.80; KW p < 0.001), while GGT (d= 0.46, 95% CI: −0.12, 1.04;
KW p= 0.07) and ALT (d= 0.22, 95% CI: −0.35, 0.79; KW p= 0.61)
alterations were not statistically significant (Fig. 3B).
Sensitivity analysis of significant non-hypertensive pathway
metabolites
After adjusting the analysis for smoking, patients still showed
reduced levels of log-transformed adiponectin (z=−2.1; p= 0.03)
compared to controls. Further, log-transformed hsCRP (z= 2.4, p
= 0.02), insulin (z= 2.2, p= 0.03), glucose (z= 2.8, p < 0.01), and
triglyceride (z= 2.7, p= 0.01) levels were elevated after adjusting
for smoking. Finally, log-transformed endothelin-1 levels did not
show a significant difference between patients and controls when
adjusting for smoking (z= 1.4, p= 0.15).
Relationship between CCR and non-hypertensive pathway
measures
Simple linear regression was used to test the association between
significantly altered non-hypertensive pathway metabolites and
participants’ concentricity values.
Table 3 shows that, after adjusting p values for multiple testing,
only log-transformed adiponectin values showed a significant
negative association with cardiac concentricity (β=−1.16, p=
0.01), explaining 20% of its variance (Supplementary Fig. 2).
Log-transformed triglycerides (β= 1.07, p= 0.02, Supplemen-
tary Fig. 3) and endothelin-1 (β= 0.50, p= 0.03, Supplementary
Fig. 4) levels showed a positive association with cardiac
concentricity; however, they did not reach the significance
threshold after adjusting for multiple testing.
Log-transformed ALP, HDL, hsCRP, and fasting glucose did not
show any significant correlation with concentricity measures
(Table 3 and Supplementary Figs. 5–8).
Lifetime antipsychotic dose (chlorpromazine equivalents*years)
did not show any significant correlation with concentricity
measures (β < 0.0001, p= 0.68) or with log-transformed adipo-
nectin levels (β < 0.0001, p= 0.81).
DISCUSSION
In this work, combining cardiac and whole-body fat MRI imaging
measures with blood assessment of various metabolic and
inflammatory markers, we investigate several molecular pathways
potentially responsible for CCR in chronic schizophrenia. We show
evidence of adipose tissue dysfunction in schizophrenia, as well as
downstream effects that might explain up to 20% of the CCR
phenotype, in the absence of case–control differences in age, sex,
ethnicity, BSA, body fat total content and distribution, and any
medical comorbidity.
We have previously shown that patients with chronic schizo-
phrenia show evidence of CCR [9] and increased myocardial T1
Table 1. Sample characteristics.
Characteristic Schizophrenia Healthy controls Test statistic
Sample size 26 24
Male sex, N (%) 18 (69%) 16 (67%) χ2= 0.01; df= 1; p= 0.99
White ethnicity, N (%) 11 (42%) 15 (62%) χ2= 1.3; df= 1; p= 0.25
Age, years, mean (SD) 39.9 (10.4) 36.9 (11.4) t= 0.97, df= 47, p= 0.34
Number of cigarettes smoked per day, median (min; max; IQR) 5 (0; 35; 18) 0 (0; 10; 0.25) KW χ2= 9.1; df= 1; p= 0.003
Smokers, N (%) 15 (57.7%) 6 (25%) χ2= 4.2; df= 1; p= 0.04
Activity score, median (IQR) 2 (0) 3 (1) KW χ2= 43.8; df= 1; p= 0.05
BSA (m2), mean (SD) 2.02 (0.30) 1.95 (0.23) t= 0.9, df= 47, p= 0.40
Body mass index (BMI) (kg/m2), mean (SD) 28.77 (7.19) 25.96 (5.19) t= 1.6, df= 45, p= 0.12
Systolic BP (mmHg), mean (SD) 123 (11) 122 (13) t= 0.34, df= 47, p= 0.73
Diastolic BP (mmHg), mean (SD) 80 (9) 77 (8) t= 1.1, df= 47, p= 0.28
Chlorpromazine equivalent dose (mg/day), median (IQR) 358.98 (221) N/A N/A
Duration of treatment (years), median (IQR) 12 (15) N/A N/A
Total PANSS score, median (IQR) 55 (29) N/A N/A
df degrees of freedom, p p value, KW χ2 Kruskal–Wallis chi squared, t t test statistic, SD standard deviation, IQR inter-quartile range, N/A not available, BSA body
surface area (calculated using Mosteller formula), BP blood pressure.
E.F. Osimo et al.
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relaxation time, which is evidence of inflammation/fibrosis [10].
We have also shown that patients with chronic schizophrenia do
not demonstrate differences in body fat content or distribution as
compared to matched HCs [30].
We confirm these findings in the present, partially overlapping
sample, with participants additionally tested for a number of
blood metabolites from the hypertensive and non-hypertensive
CCR pathways. Here we also show that CCR in people with
schizophrenia might have a different aetiology from that of the
general population, i.e. it does not appear to be associated with
the most common pathological stimuli, such as pressure overload
(no difference in systolic or diastolic BP in schizophrenia vs HC),
which usually leads to stiffening of the aorta (PWV not significantly
elevated), and activation of the renin–angiotensin axis (no active
renin elevation).
Despite no differences in body fat content or distribution, we
show that patients with schizophrenia do manifest adipose tissue
dysfunction, as evidenced by low adiponectin levels. Low levels of
adiponectin are associated with a more atherogenic lipid profile,
including increases in triglycerides and LDL, and reductions in HDL
[20]; a similar pattern of association suggestive of adiponectin
effects was present in this study but will require confirmation in
larger, better powered samples. Previous evidence supports our
findings by suggesting that adiponectin, leptin, and their ratio
might be useful prognostic markers of metabolic syndrome in
schizophrenia [34].
Further, a dyslipidaemic phenotype has been associated with
chronic inflammatory states [18, 19], and indeed we show
significant elevations in CRP in our sample, which has been
associated with NAFLD [22]. Although we did not measure liver fat
content directly in this study, we found significantly elevated
levels of ALP, a liver function marker, and triglycerides, suggestive
of NAFLD. These findings agree with reports in the literature that
the prevalence of NAFLD is higher in patients with schizophrenia
than in the wider population [35]. As adiponectin has been shown
to decrease in response to smoking in the general population [36],
we were also able to show that low adiponectin levels in
schizophrenia appear independent of the increased rate of
smoking in this patient population.
Finally, there are known causal associations between low
adiponectin and insulin resistance [19], which we show evidence
of in schizophrenia, as well as between low adiponectin and
endothelial dysfunction [21], and indeed we find that endothelin-1
is significantly elevated in schizophrenia.
We also demonstrate a negative correlation between adipo-
nectin levels (the first step in the pathway) and concentricity
values (the end result), which supports a potentially causal role.
Further, our analysis shows that one-fifth (20%) of the variance of
concentricity is explained by adiponectin levels in our sample.
Implications of our findings
We have recently shown that schizophrenia is characterised by
CCR [9], which could explain part of the additional cardiovascular
mortality in schizophrenia, as CCR has been shown to be
associated with cardiovascular events in healthy adults [11].
By combining blood and imaging measures, in this study we
take a step forward, by showing that adipose tissue dysfunction,
and particularly reductions in adiponectin, may play a role in
orchestrating multiple dysmetabolic changes in schizophrenia,
independently of changes in BP. We did not find case–control
differences in leptin; however, as leptin is usually a reflection of
subcutaneous fat content, this lack of a significant difference is in
agreement with our findings of no differences in body fat content
or distribution in patients with schizophrenia.
Adiponectin is secreted by adipocytes, decreasing when fat
mass increases, such as in obesity or metabolic syndrome, in a
negative feedback loop [37]. Dysfunctional adipocytes produce
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cytokines, which further inhibit the production of adiponectin in
adipocytes. Adiponectin expression by adipocytes is also inhibited
by oxidant stress [38]. Adiponectin levels are strongly negatively
correlated with CVD: adiponectin concentrations in the plasma are
reduced in coronary artery disease (CAD) patients, compared to
age- and BMI-adjusted control subjects [39], and high adiponectin
levels are associated with lower risk of CAD in healthy men [40].
Finally, adiponectin reductions are associated with increased CRP
and other pro-inflammatory cytokines [18, 19], insulin resistance
[19], elevated plasma triglycerides and lipoproteins [20], and
Fig. 3 Concentric cardiac remodelling non-hypertensive pathway activity in schizophrenia vs healthy controls. A Markers of adipocyte
dysfunction. B Markers of dyslipidaemia or liver dysfunction (e.g. NAFLD). C Markers of inflammation, dysglycaemia, and endothelial
dysfunction. p Kruskal–Wallis non-parametric test p value, HC healthy control, CS chronic schizophrenia, ALP alkaline phosphatase, GGT
gamma-glutamyltransferase, ALT alanine aminotransferase, LDL and HDL low- and high-density lipoprotein, hsCRP high-sensitivity C-reactive
protein, HOMA-IR Homeostatic Model Assessment for Insulin Resistance.
E.F. Osimo et al.
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endothelial dysfunction [21] in the general population. As
inflammation [25], insulin resistance [26], NAFLD [27], hyperlipi-
daemias [13], and endothelial dysfunction [28] can all indepen-
dently trigger CCR, adipose tissue dysfunction, with its associated
downstream effects, might represent a plausible non-hypertensive
pathway to CCR in schizophrenia.
We therefore postulate that schizophrenia may be characterised
by adipose tissue dysfunction, and this may contribute to CCR and
increases in the risk of CVD, and ultimately in additional mortality.
If confirmed in larger prospective studies, these findings would
suggest that reparative and preventative strategies could be
aimed at restoring balance to the adipose tissue system, even in
the absence of macroscopic changes to the body’s fat mass.
Strengths and limitations
The main strength of this study is the integration of multiple
methods and investigation techniques, including clinical pheno-
types, cardiac and fat MRI, and blood markers, all in the same
sample. The integration of imaging and biochemical sampling in a
select population with severe mental illness did constrain the
number of participants that we could enrol and consequently
sample size. It is therefore possible that some of the negative
findings in this work might be the result of a type II statistical error.
A further strength is represented by the use of gold standard
techniques for measuring cardiac, body fat, and blood pheno-
types, allowing all measurements to be analysed by operators
blind to diagnosis. For cardiac phenotypes, we utilised cardiovas-
cular magnetic resonance (CMR), which is the gold standard for LV
function and mass quantification [29]. A key advantage of CMR
over echocardiography is that the ventricles can be imaged in
their entirety, and no geometrical assumptions need to be made
in order to derive global whole-organ data [41]. Body fat contents
and distribution was measured using gold standard whole-body
MRI, which has been shown to outperform other techniques such
as body impedance by not providing underestimates of body
mass overall [42], and more accurate quantification of the visceral
compartment [43].
A third major strength of this study is that we excluded any
participants with a pre-existing medical condition, including heart
disease, hypertension, diabetes, or dyslipidaemia, and we
matched patients and controls for BSA, age, sex and ethnicity,
all potential confounders in analyses of cardiometabolic function
[29, 44–46]. However, while we excluded diagnosed cardiometa-
bolic disorders, we cannot exclude the possibility of subclinical
changes, although we found no significant difference between
cases and controls in systolic or diastolic BP or PWV, suggesting
subclinical differences are unlikely to be large.
The main limitation of this study is that it involved chronic
patients (median duration of treatment of 12 years), who were all
taking metabolically active antipsychotic medications, mainly
clozapine. Olanzapine and clozapine in particular are known to
have dysmetabolic effects [47]. It is therefore possible that adipose
tissue dysfunction in schizophrenia is mediated at least in part by
their use. Bartoli et al. found that adiponectin may be significantly
reduced in chronic patients taking second-generation antipsycho-
tics (SGAs), with non-significant findings in a smaller sample of
antipsychotic-free patients [17]. Multiple reports associate treat-
ment with olanzapine or clozapine (not risperidone) with
adiponectin reductions [17, 48], suggesting that the effect may
be medication specific. However, in the current study, where all
participants were chronic patients taking SGA, mostly clozapine,
we did not find a linear relationship between total lifetime
chlorpromazine equivalents and either concentricity or adiponec-
tin levels. In any respect, a future study in antipsychotic-naive
patients, who already show pro-inflammatory [49] and dysmeta-
bolic changes [50], would be useful to determine whether the
cardiac and adipokine changes we have detected are already
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A final limitation is the absence of liver imaging or spectroscopy
to directly assess liver fat content; however, we relied on a panel
of blood tests to indirectly assess the risk of NAFLD.
CONCLUSIONS AND FUTURE DIRECTIONS
In participants with chronic schizophrenia with evidence of CCR,
we found no differences in adipose tissue content or regional
distribution or hypertension compared to well-matched HCs,
despite reductions in adiponectin. We hypothesise that cardiac
changes may originate from adipose tissue dysfunction and its
downstream effectors, potentially mediated by significant reduc-
tions in adiponectin.
The role of adipose tissue dysfunction in schizophrenia, and in
particular the role of circulating adiponectin levels, could provide
a useful biomarker to classify cardiovascular risk in patients with
schizophrenia, as it has already shown to have potential as a
predictor of developing metabolic syndrome in this same cohort
[51, 52]. Additionally, it raises the potential for interesting
therapeutic avenues to reduce cardiovascular risk in certain
patients.
Adiponectin levels in schizophrenia need further investigation,
and the preliminary finding that they are reduced in chronic
patients on SGAs [17] should encourage further research on the
effects of specific antipsychotics on adipose tissue function.
REFERENCES
1. McCutcheon RA, Marques TR, Howes OD. Schizophrenia—an overview. JAMA
Psychiatry. 2020;77:201–10.
2. Harris C, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry.
1998;173:11–53.
3. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular
mortality in persons with schizophrenia. Curr Opin psychiatry. 2012;25:83–8.
4. Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V,
et al. A comprehensive analysis of mortality-related health metrics associated
with mental disorders: a nationwide, register-based cohort study. Lancet.
2019;394:1827–35.
5. Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet
Psychiatry Commission: a blueprint for protecting physical health in people with
mental illness. Lancet Psychiatry. 2019;6:675–712.
6. De Hert M, Detraux J, Vancampfort D. The intriguing relationship between cor-
onary heart disease and mental disorders. Dialogues Clin Neurosci. 2018;20:31.
7. Laursen TM. Life expectancy among persons with schizophrenia or bipolar
affective disorder. Schizophr Res. 2011;131:101–4.
8. Parks J, Svendsen D, Singer P, Foti ME, Mauer B. Morbidity and mortality in people
with serious mental illness. Alexandria, VA: National Association of State Mental
Health Program Directors (NASMHPD) Medical Directors Council; 2006.
9. Osimo EF, Brugger SP, de Marvao A, Pillinger T, Whitehurst T, Statton B, et al.
Cardiac structure and function in schizophrenia: a cardiac MR imaging study. Br J
Psychiatry. 2020;217:450–7.
10. Pillinger T, Osimo EF, de Marvao A, Berry MA, Whitehurst T, Statton B, et al.
Cardiac structure and function in patients with schizophrenia taking anti-
psychotic drugs: an MRI study. Transl Psychiatry. 2019;9:163.
11. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, et al. Left ven-
tricular structure and risk of cardiovascular events: a Framingham Heart Study
Cardiac Magnetic Resonance Study. J Am Heart Assoc. 2015;4:e002188.
12. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of
fibrosis with mortality and sudden cardiac death in patients with nonischemic
dilated cardiomyopathy. JAMA. 2013;309:896–908.
13. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac
hypertrophy. Nat Rev Cardiol. 2018;15:387–407.
14. Sapra M, Lawson D, Iranmanesh A, Varma A. Adiposity-independent hypoadi-
ponectinemia as a potential marker of insulin resistance and inflammation in
schizophrenia patients treated with second generation antipsychotics. Schizophr
Res. 2016;174:132–6.
15. Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic syn-
drome. Rev Endocr Metab Disord. 2014;15:277–87.
16. Yudkin JS, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy sub-
jects: associations with obesity, insulin resistance, and endothelial dysfunction: a
potential role for cytokines originating from adipose tissue? Arterioscler Thromb
Vasc Biol. 1999;19:972–8.
17. Bartoli F, Lax A, Crocamo C, Clerici M, Carrà G. Plasma adiponectin levels in
schizophrenia and role of second-generation antipsychotics: a meta-analysis.
Psychoneuroendocrinology. 2015;56:179–89.
18. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy
Clin Immunol. 2008;121:326–30.
19. Mojiminiyi O, Abdella N, Al Arouj M, Nakhi AB. Adiponectin, insulin resistance and
clinical expression of the metabolic syndrome in patients with type 2 diabetes.
Int J Obes. 2007;31:213–20.
20. Christou G, Kiortsis D. Adiponectin and lipoprotein metabolism. Obes Rev.
2013;14:939–49.
21. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadi-
ponectinemia is closely linked to endothelial dysfunction in man. J Clin Endo-
crinol Metab. 2003;88:3236–40.
22. Ikejima K, Lang T, Yamashina S, Enomoto N, Takei Y, Sato N. Role of leptin in
pathogenesis of NASH. In: Okita K, editor. NASH and nutritional therapy. Tokyo:
Springer; 2005. pp. 44–9.
23. Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastro-
enterology. 2016;150:1769–77.
24. Morlán-Coarasa MJ, Arias-Loste MT, de la Foz VO-G, Martínez-García O, Alonso-
Martín C, Crespo J, et al. Incidence of non-alcoholic fatty liver disease and
metabolic dysfunction in first episode schizophrenia and related psychotic dis-
orders: a 3-year prospective randomized interventional study. Psychopharma-
cology. 2016;233:3947–52.
25. Fang L, Ellims AH, Beale AL, Taylor AJ, Murphy A, Dart AM. Systemic inflammation
is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hyper-
trophy in patients with hypertrophic cardiomyopathy. Am J Transl Res.
2017;9:5063.
26. Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and cardiac remo-
deling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis.
2018;61:114–23.
27. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd‐Jones DM, Carr JJ, Lima JA, et al.
Association of nonalcoholic fatty liver disease with subclinical myocardial
remodeling and dysfunction: a population‐based study. Hepatology.
2015;62:773–83.
28. Archer CR, Robinson EL, Drawnel FM, Roderick HL. Endothelin-1 promotes
hypertrophic remodelling of cardiac myocytes by activating sustained signalling
and transcription downstream of endothelin type A receptors. Cell Signal.
2017;36:240–54.
29. American College of Cardiology Foundation Task Force on Expert Consensus
Documents, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, et al. ACCF/
ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular
magnetic resonance: a report of the American College of Cardiology Foundation
Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;55:2614–62.
30. Osimo EF, Brugger SP, Thomas EL, Howes OD. Body fat volumes and distribution
in chronic schizophrenia compared to healthy controls; a cross-sectional MR
study. medRxiv:2021.2009.2020.21263820 [Preprint]. 2021 [cited 2021 Sep 22]:
[11 p.]. Available from: https://doi.org/10.1101/2021.09.20.21263820.
31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS)
for schizophrenia. Schizophr Bull. 1987;13:261–76.
32. Matthews DR, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis
model assessment: insulin resistance and β-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
33. Torchiano M. Effsize - a package for efficient effect size computation. zenodo.
2016. https://zenodo.org/record/1480624#.YaNWyaJ5pPY.
34. Chen VC-H, Chen C-H, Chiu Y-H, Lin T-Y, Li F-C, Lu M-L. Leptin/adiponectin ratio as
a potential biomarker for metabolic syndrome in patients with schizophrenia.
Psychoneuroendocrinology. 2018;92:34–40.
35. Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizo-
phrenics with non-alcoholic fatty liver disease. Neuropsych Dis Treat.
2017;13:1493.
36. Park SK, Ryoo J-H, Kang JG, Jung JY. Smoking status, intensity of smoking, and
their relation to left ventricular hypertrophy in working aged Korean men.
Nicotine Tob Res. 2021;23:1176–82.
37. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adi-
ponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.
38. Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue
microenvironment and their impact on cardiovascular disease. Circ Res.
2016;118:1786–807.
39. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel mod-
ulator for endothelial adhesion molecules: adipocyte-derived plasma protein
adiponectin. Circulation. 1999;100:2473–6.
40. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adipo-
nectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.
41. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, et al. Comparison
of left ventricular ejection fraction and volumes in heart failure by
E.F. Osimo et al.
8
Translational Psychiatry          (2021) 11:614 
echocardiography, radionuclide ventriculography and cardiovascular magnetic
resonance. Are they interchangeable? Eur Heart J. 2000;21:1387–96.
42. Forde C, Murphy N, Meaney J, Kennedy P, Boyle G. Comparison of bioelectrical
impedance analysis and magnetic resonance imaging for the quantification of fat
mass. Int J Physiatry. 2015;1:003
43. Chaudry O, Grimm A, Friedberger A, Kemmler W, Uder M, Jakob F, et al. Magnetic
resonance imaging and bioelectrical impedance analysis to assess visceral and
abdominal adipose tissue. Obesity. 2020;28:277–83.
44. Wong ND, Gardin JM, Kurosaki T, Anton-Culver H, Sidney S, Roseman J, et al.
Echocardiographic left ventricular systolic function and volumes in young adults:
distribution and factors influencing variability. Am Heart J. 1995;129:571–7.
45. Aijaz B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ.
Abnormal cardiac structure and function in the metabolic syndrome: a
population-based study. Mayo Clin Proc. 2008;83:1350–7.
46. Cheitlin MD. Cardiovascular physiology—changes with aging. Am J Geriatr Car-
diol. 2003;12:9–13.
47. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al.
Comparative effects of 18 antipsychotics on metabolic function in patients with
schizophrenia, predictors of metabolic dysregulation, and association with psy-
chopathology: a systematic review and network meta-analysis. Lancet Psychiatry.
2020;7:64–77.
48. Lu M-L, Wang T-N, Lin T-Y, Shao W-C, Chang S-H, Chou J-Y, et al. Differential
effects of olanzapine and clozapine on plasma levels of adipocytokines and total
ghrelin. Prog Neuropsychopharmacol Biol Psychiatry. 2015;58:47–50.
49. Pillinger T, Osimo EF, Brugger S, Mondelli V, McCutcheon RA, Howes OD. A meta-
analysis of immune parameters, variability, and assessment of modal distribution
in psychosis and test of the immune subgroup hypothesis. Schizophr Bull.
2019;45:1120–33.
50. Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-
episode psychosis: systematic review and meta-analysis. Br J Psychiatry.
2017;211:339–49.
51. Bai YM, Chen J-Y, Yang W-S, Chi Y-C, Liou Y-J, Lin C-C, et al. Adiponectin as a
potential biomarker for the metabolic syndrome in Chinese patients taking clo-
zapine for schizophrenia. J Clin Psychiatry. 2007;68:1834–9.
52. Bai YM, Chen TT, Yang W-S, Chi Y-C, Lin C-C, Liou Y-J, et al. Association of
adiponectin and metabolic syndrome among patients taking atypical anti-
psychotics for schizophrenia: a cohort study. Schizophr Res. 2009;111:1–8.
53. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turk-
bey EB, Williams R, et al. Normal values for cardiovascular magnetic resonance in
adults and children. J Cardiovasc Magn Reson. 2015;17:29.
54. Corden B, Keenan NG, de Marvao AS, Dawes TJ, DeCesare A, Diamond T, et al.
Body fat is associated with reduced aortic stiffness until middle age. Hyperten-
sion. 2013;61:1322–7.
AUTHOR CONTRIBUTIONS
EFO contributed to the design of the study, coordinated data collection, recruited
and scanned participants, performed data analyses, and drafted the manuscript. MS
and AdM contributed to study design, cardiac image analysis, and contributed to the
manuscript by providing invaluable insight into the cardiometabolic aspects of the
analysis and discussion. TP and TW contributed to participant recruitment and
scanning and contributed to the manuscript. SAC, ELT, and BIP contributed to the
manuscript. DPO’R supervised data analyses and contributed to the manuscript. ODH
conceived and designed the study, supervised data analyses, and contributed to the
manuscript. All authors have approved the final manuscript.
FUNDING INFORMATION
This work was funded by a Clinical PhD Fellowship to EFO jointly funded by the
National Institute for Health Research (NIHR) Imperial Biomedical Research Centre
(BRC) and the Medical Research Council (MRC) London Institute of Medical Sciences
(LMS) and by the BMA Foundation for Medical Research (Margaret Temple 2020
grant) to EFO and ODH. This study was also funded by grants MC-A656-5QD30 from
the Medical Research Council-UK and the NIHR Biomedical Research Centre South
London and Maudsley Foundation NHS Trust to ODH.
COMPETING INTERESTS
SAC is a co-founder and director of Enleofen Bio PTE LTD, a company that develops
anti-IL-11 therapeutics. Enleofen Bio had no involvement in this study. ODH is a part-
time employee of H Lundbeck A/s. He has received investigator-initiated research
funding from and/or participated in advisory/speaker meetings organised by
Angelini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical
Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati,
Roche, and Viatris/Mylan. ODH has a patent for the use of dopaminergic imaging.
DPO’R has received grant funding from Bayer AG. None of these had any
involvement in this study. TP has participated in educational speaker meetings
organised by Lundbeck, Otsuka, Sunovion, Schwabe Pharma, and Recordati. All other
authors report no conflicts of interest.
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41398-021-01741-9.
Correspondence and requests for materials should be addressed to Emanuele F.
Osimo or Oliver D. Howes.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
E.F. Osimo et al.
9
Translational Psychiatry          (2021) 11:614 
